|
Alzheimer's Disease
|
0.310 |
Biomarker
|
disease |
CTD_human |
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease.
|
25992776 |
2015 |
|
Alzheimer's Disease
|
0.310 |
Biomarker
|
disease |
BEFREE |
Seven miRNAs (miR-206, miR-132, miR-193b, miR-130b, miR-20a, miR-296, and miR-329) related to Alzheimer's disease (AD) were detected in serum using a quantitative real-time PCR (qRT-PCR) method.
|
25589731 |
2015 |
|
Presenile dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease.
|
25992776 |
2015 |
|
Familial Alzheimer Disease (FAD)
|
0.300 |
Biomarker
|
disease |
CTD_human |
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease.
|
25992776 |
2015 |
|
Alzheimer Disease, Late Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease.
|
25992776 |
2015 |
|
Acute Confusional Senile Dementia
|
0.300 |
Biomarker
|
disease |
CTD_human |
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease.
|
25992776 |
2015 |
|
Alzheimer's Disease, Focal Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease.
|
25992776 |
2015 |
|
Alzheimer Disease, Early Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease.
|
25992776 |
2015 |
|
Myocardial Reperfusion Injury
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Modulation of microRNA 20b with resveratrol and longevinex is linked with their potent anti-angiogenic action in the ischaemic myocardium and synergestic effects of resveratrol and γ-tocotrienol.
|
22050707 |
2012 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Subsequently, the in vivo experiments further verified that the FOXD3-AS1/miR-296-5p axis exerted obvious anti-tumor effect through inhibiting tumor growth and metastasis and the TGF-β1/Smads signaling pathway was also inactivated in vivo by the inhibition of FOXD3-AS1.
|
31678422 |
2020 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The miRDB and expression analysis in cancer cell lines for the 10 miRNAs identified miR-296-5p and miR-1207-5p as biomarkers predictive of shorter survival (p < 0.0005).
|
31563901 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Overexpressed miR-296-5p suppressed cell proliferation and metastasis.
|
31565837 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
CircPSMC3 suppresses the proliferation and metastasis of gastric cancer by acting as a competitive endogenous RNA through sponging miR-296-5p.
|
30777076 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Experiments <i>in vitro</i> and <i>in vivo</i> were conducted to explore the effects of circPLK1 on tumor proliferation and metastasis as well as the interaction between circPLK1, miR-296-5p and <i>PLK1</i> in TNBC.
|
31337246 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-296 functions as a tumor suppressor in breast cancer by targeting FGFR1 and regulating the Wnt/β-catenin signaling pathway.
|
31841196 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, the findings demonstrated that miR-296-3p may function as a tumor suppressor, and inhibits the migration and invasion of NSCLC cells by targeting APEX1. miR-296-3p is therefore a potential therapeutic molecular modulator of NSCLC.
|
31402954 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings proved that miR-296-3p may play a role as a tumor suppressor in NSCLC both in vitro and in vivo, and we first reported that miR-296-3p can regulate the migration and invasion of A549 cells via targeting RABL3.
|
31298353 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results demonstrated that miR-296 is a critical tumor suppressor which was downregulated in CRC patients.
|
30365090 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The miRDB and expression analysis in cancer cell lines for the 10 miRNAs identified miR-296-5p and miR-1207-5p as biomarkers predictive of shorter survival (p < 0.0005).
|
31563901 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we summarize and discuss the most recent findings regarding miR-296 in cancer, including its downstream targets, functional effects, underlying regulatory mechanisms, and therapeutic potentials.
|
30293950 |
2018 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Six pro-angiogenic miRNAs including miR-17-5p, miR-92a, miR-210, miR-20a, miR-18a, and miR-296 expressions were positively while 1 pro-angiogenic miRNA (miR-130a) was negatively correlated with tumor malignancy degree in GC patients.
|
30003708 |
2018 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results reveal a novel mechanism by which miR-296-3p negatively regulated by nicotine directly targets MK2-induced Ras/Braf/Erk/Mek/c-Myc or PI3K/AKT/c-Myc signaling to stimulate its own expression and suppress NPC cell proliferation and metastasis. miR-296-3p may thus serve as a therapeutic target to reverse chemotherapy resistance of NPC.
|
29525743 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bio-informatics prediction and our experiments validated that MMP-2 and MMP-9 were simultaneously targeted by miR-296-3p and FOXC1 promoter upstream transcript (FOXCUT); the latter two exerted tumor-suppressing effects on CMM cells by inhibiting cell proliferation, cell cycle progression, migration, invasion, and induction of cell apoptosis.
|
29260433 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicated that miR-296 may act as a tumor suppressor in cervical cancer by directly targeting SP1.
|
29241478 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Six pro-angiogenic miRNAs including miR-17-5p, miR-92a, miR-210, miR-20a, miR-18a, and miR-296 expressions were positively while 1 pro-angiogenic miRNA (miR-130a) was negatively correlated with tumor malignancy degree in GC patients.
|
30003708 |
2018 |